METROPOLIS Stock Overview
Provides diagnostic services in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
No risks detected for METROPOLIS from our risk checks.
Metropolis Healthcare Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,015.75 |
| 52 Week High | ₹2,318.30 |
| 52 Week Low | ₹1,450.00 |
| Beta | 0.34 |
| 11 Month Change | -5.51% |
| 3 Month Change | -2.40% |
| 1 Year Change | 24.24% |
| 33 Year Change | -31.61% |
| 5 Year Change | 43.72% |
| Change since IPO | 110.01% |
Recent News & Updates
Recent updates
Metropolis Healthcare Limited (NSE:METROPOLIS) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 13
Metropolis Healthcare Limited (NSE:METROPOLIS) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 14Metropolis Healthcare Limited Just Missed EPS By 5.7%: Here's What Analysts Think Will Happen Next
May 24Why Investors Shouldn't Be Surprised By Metropolis Healthcare Limited's (NSE:METROPOLIS) P/E
Mar 28Capital Allocation Trends At Metropolis Healthcare (NSE:METROPOLIS) Aren't Ideal
Jan 13Metropolis Healthcare Limited's (NSE:METROPOLIS) Share Price Matching Investor Opinion
Dec 23Does Metropolis Healthcare (NSE:METROPOLIS) Have A Healthy Balance Sheet?
Sep 08Metropolis Healthcare (NSE:METROPOLIS) Could Be Struggling To Allocate Capital
Jun 20Metropolis Healthcare (NSE:METROPOLIS) Might Be Having Difficulty Using Its Capital Effectively
Mar 14Metropolis Healthcare's (NSE:METROPOLIS) Dividend Will Be ₹8.00
Feb 13Metropolis Healthcare Limited's (NSE:METROPOLIS) Intrinsic Value Is Potentially 25% Below Its Share Price
Sep 25Is Metropolis Healthcare (NSE:METROPOLIS) A Risky Investment?
Sep 10Metropolis Healthcare (NSE:METROPOLIS) Has A Rock Solid Balance Sheet
Jun 07Capital Investments At Metropolis Healthcare (NSE:METROPOLIS) Point To A Promising Future
May 16Is Now The Time To Put Metropolis Healthcare (NSE:METROPOLIS) On Your Watchlist?
Mar 17Capital Investments At Metropolis Healthcare (NSE:METROPOLIS) Point To A Promising Future
Jan 29Do Metropolis Healthcare's (NSE:METROPOLIS) Earnings Warrant Your Attention?
Dec 14Metropolis Healthcare (NSE:METROPOLIS) Looks To Prolong Its Impressive Returns
Oct 12Should You Be Adding Metropolis Healthcare (NSE:METROPOLIS) To Your Watchlist Today?
Aug 27Here's What Metropolis Healthcare's (NSE:METROPOLIS) Strong Returns On Capital Mean
Jul 06Shareholder Returns
| METROPOLIS | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | -0.8% | 0.8% | 0.3% |
| 1Y | 24.2% | 36.4% | 27.3% |
Return vs Industry: METROPOLIS underperformed the Indian Healthcare industry which returned 36.4% over the past year.
Return vs Market: METROPOLIS underperformed the Indian Market which returned 27.3% over the past year.
Price Volatility
| METROPOLIS volatility | |
|---|---|
| METROPOLIS Average Weekly Movement | 3.5% |
| Healthcare Industry Average Movement | 5.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: METROPOLIS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: METROPOLIS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 4,313 | Surendran Chemmenkotil | www.metropolisindia.com |
Metropolis Healthcare Limited provides diagnostic services in India and internationally. The company offers clinical laboratory testing, and profiles services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, and youth and corporates.
Metropolis Healthcare Limited Fundamentals Summary
| METROPOLIS fundamental statistics | |
|---|---|
| Market cap | ₹103.60b |
| Earnings (TTM) | ₹1.48b |
| Revenue (TTM) | ₹12.85b |
69.8x
P/E Ratio8.0x
P/S RatioIs METROPOLIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| METROPOLIS income statement (TTM) | |
|---|---|
| Revenue | ₹12.85b |
| Cost of Revenue | ₹2.84b |
| Gross Profit | ₹10.01b |
| Other Expenses | ₹8.53b |
| Earnings | ₹1.48b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 28.87 |
| Gross Margin | 77.88% |
| Net Profit Margin | 11.52% |
| Debt/Equity Ratio | 0% |
How did METROPOLIS perform over the long term?
See historical performance and comparison